Profile picture

Ms Dongqing Chen

University of Newcastle, Newcastle (Australia)
Follow
Logo ESC

Contributor content

The clinically active PARP inhibitor olaparib ameliorates doxorubicin-induced cardiotoxicity in both in vitro and in vivo model
Presentation
The clinically active PARP inhibitor olaparib ameliorates doxorubicin-induced cardiotoxicity in both in vitro and in vivo model
Read more
Doxorubicin-induced upregulation of follistatin-like 3 (FSTL3): a new therapeutic target
Presentation
Doxorubicin-induced upregulation of follistatin-like 3 (FSTL3): a new therapeutic target
Read more
Follistatin-like 3 (FSTL3) levels are increased in acute heart failure patients
Presentation
Follistatin-like 3 (FSTL3) levels are increased in acute heart failure patients
Read more

ESC 365 is supported by

novartis Explore sponsored resources